# Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant

> **NCT05670379** · PHASE1 · COMPLETED · sponsor: **Vivani Medical, Inc** · enrollment: 24 (actual)

## Conditions studied

- Overweight and Obesity
- Type2diabetes

## Interventions

- **COMBINATION_PRODUCT:** Exenatide Implant
- **DRUG:** Bydureon BCise (exenatide extended release)
- **DRUG:** Semaglutide, 1.0 mg/mL

## Key facts

- **NCT ID:** NCT05670379
- **Lead sponsor:** Vivani Medical, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-20
- **Primary completion:** 2025-08-21
- **Final completion:** 2025-08-21
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05670379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05670379, "Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05670379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*